{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/48310"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/48310","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"The optimal cutoff values of high-sensitivity troponin and NT-proBNP for the risk-stratification of patients with acute pulmonary embolism","abstract":"BACKGROUND: Current guidelines recommend using high-sensitivity troponin T (HST) to risk-stratify hemodynamically stable patients with acute pulmonary embolism (PE). N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can also be used in the risk-stratification of acute PE patients, but there are no established cutoff values for either of these assays to identify PE patients at risk for clinical decompensation. AIMS: To determine the optimal cutoff of HST and NT-proBNP for the risk-stratification of acute PE. METHODS: We retrospectively analyzed data from a prospectively collected, single-center registry of patients evaluated by our Pulmonary Embolism Response Team (PERT). This registry is IRB approved with a waiver of informed consent. We included patients with a confirmed PE who had either an HST value (Elecsys Troponin T Gen 5 STAT, Roche Diagnostics) or NT-proBNP value (Elecsys proBNP II STAT, Roche Diagnostics) measured clinically. We used the highest HST and NT-proBNP value within 24 hours of PERT activation. We excluded patients with unstable vital signs on presentation. Our primary outcome was a composite of death, thrombolysis, thrombectomy, endotracheal intubation, extracorporeal membrane oxygenation (ECMO), or ICU admission, within 7 days. We calculated the area under the ROC curve for HST and NT-proBNP and established the optimal cutoff using the distance from (0,1). We performed subgroup analyses limited to patients with intermediate-risk PE. RESULTS: We screened 815 PE patients from 10/2012 – 06/2021 with an NT-proBNP value measured, of whom 727 were hemodynamically stable. The high-sensitivity troponin assay was first implemented at MGH in April 2018; therefore, we screened 368 consecutive PE patients from 04/2018 – 06/2021, of whom 243 were hemodynamically stable. Of those, 234 (96%) had HST values measured. For both the HST and NT-proBNP populations, the mean age was 62 ± 17 years and 53% were male (Tables 8-9). Overall, the AUC for HST was 0.64 (95% CI, 0.56-0.71) with an optimal cutoff of 46 ng/L (Figure 6a), corresponding to sensitivity 59% (95% CI, 49%-69%) and specificity 61% (95% CI, 53%-69%). The AUC for NT-proBNP overall was 0.56 (95% CI, 0.51-0.61) with an optimal cutoff of 1092 pg/mL (Figure 7a), corresponding to sensitivity 53% (95% CI, 45%-61%) and specificity 59% (95% CI, 55%-63%). Among intermediate-risk PE, the AUC for HST was 0.60 (95% CI, 0.52-0.69) with an optimal cutoff of 46 ng/L (Figure 6b), sensitivity 62% (95% CI, 50%-73%) and specificity 53% (95% CI, 44%-63%); and the AUC for NT-proBNP was 0.56 (95% CI, 0.48-0.64) with an optimal cutoff of 1158 pg/mL (Figure 7b), sensitivity 57% (95% CI, 46%-68%) and specificity 56% (95% CI, 47-64%). CONCLUSION: We identified an optimal cutoff for HST of 46 ng/L and for NT-proBNP of 1092 pg/mL, though the AUC suggests low to moderate performance for the risk stratification of hemodynamically stable PE.","abstract_html":"BACKGROUND: Current guidelines recommend using high-sensitivity troponin T (HST) to risk-stratify hemodynamically stable patients with acute pulmonary embolism (PE). N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can also be used in the risk-stratification of acute PE patients, but there are no established cutoff values for either of these assays to identify PE patients at risk for clinical decompensation. AIMS: To determine the optimal cutoff of HST and NT-proBNP for the risk-stratification of acute PE. METHODS: We retrospectively analyzed data from a prospectively collected, single-center registry of patients evaluated by our Pulmonary Embolism Response Team (PERT). This registry is IRB approved with a waiver of informed consent. We included patients with a confirmed PE who had either an HST value (Elecsys Troponin T Gen 5 STAT, Roche Diagnostics) or NT-proBNP value (Elecsys proBNP II STAT, Roche Diagnostics) measured clinically. We used the highest HST and NT-proBNP value within 24 hours of PERT activation. We excluded patients with unstable vital signs on presentation. Our primary outcome was a composite of death, thrombolysis, thrombectomy, endotracheal intubation, extracorporeal membrane oxygenation (ECMO), or ICU admission, within 7 days. We calculated the area under the ROC curve for HST and NT-proBNP and established the optimal cutoff using the distance from (0,1). We performed subgroup analyses limited to patients with intermediate-risk PE. RESULTS: We screened 815 PE patients from 10/2012 – 06/2021 with an NT-proBNP value measured, of whom 727 were hemodynamically stable. The high-sensitivity troponin assay was first implemented at MGH in April 2018; therefore, we screened 368 consecutive PE patients from 04/2018 – 06/2021, of whom 243 were hemodynamically stable. Of those, 234 (96%) had HST values measured. For both the HST and NT-proBNP populations, the mean age was 62 ± 17 years and 53% were male (Tables 8-9). Overall, the AUC for HST was 0.64 (95% CI, 0.56-0.71) with an optimal cutoff of 46 ng/L (Figure 6a), corresponding to sensitivity 59% (95% CI, 49%-69%) and specificity 61% (95% CI, 53%-69%). The AUC for NT-proBNP overall was 0.56 (95% CI, 0.51-0.61) with an optimal cutoff of 1092 pg/mL (Figure 7a), corresponding to sensitivity 53% (95% CI, 45%-61%) and specificity 59% (95% CI, 55%-63%). Among intermediate-risk PE, the AUC for HST was 0.60 (95% CI, 0.52-0.69) with an optimal cutoff of 46 ng/L (Figure 6b), sensitivity 62% (95% CI, 50%-73%) and specificity 53% (95% CI, 44%-63%); and the AUC for NT-proBNP was 0.56 (95% CI, 0.48-0.64) with an optimal cutoff of 1158 pg/mL (Figure 7b), sensitivity 57% (95% CI, 46%-68%) and specificity 56% (95% CI, 47-64%). CONCLUSION: We identified an optimal cutoff for HST of 46 ng/L and for NT-proBNP of 1092 pg/mL, though the AUC suggests low to moderate performance for the risk stratification of hemodynamically stable PE.","abstract_has_math":false,"creators":["Matthews, Timothy M."],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Trinkaus-Randall, Vickery E.","Kabrhel, Christopher"],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-11-18T20:21:04Z","subjects":["Medicine"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/48310","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/48310","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F48310","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Trinkaus-Randall, Vickery E.","Kabrhel, Christopher"]},{"key":"dc:creator","label":"Author","values":["Matthews, Timothy M."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-03-05T19:07:25Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-03-05T19:07:25Z"]},{"key":"dc:date.issued","label":"Date","values":["2023"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2024-03-01T20:04:40Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/48310"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["BACKGROUND: Current guidelines recommend using high-sensitivity troponin T (HST) to risk-stratify hemodynamically stable patients with acute pulmonary embolism (PE). N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can also be used in the risk-stratification of acute PE patients, but there are no established cutoff values for either of these assays to identify PE patients at risk for clinical decompensation. AIMS: To determine the optimal cutoff of HST and NT-proBNP for the risk-stratification of acute PE. METHODS: We retrospectively analyzed data from a prospectively collected, single-center registry of patients evaluated by our Pulmonary Embolism Response Team (PERT). This registry is IRB approved with a waiver of informed consent. We included patients with a confirmed PE who had either an HST value (Elecsys Troponin T Gen 5 STAT, Roche Diagnostics) or NT-proBNP value (Elecsys proBNP II STAT, Roche Diagnostics) measured clinically. We used the highest HST and NT-proBNP value within 24 hours of PERT activation. We excluded patients with unstable vital signs on presentation. Our primary outcome was a composite of death, thrombolysis, thrombectomy, endotracheal intubation, extracorporeal membrane oxygenation (ECMO), or ICU admission, within 7 days. We calculated the area under the ROC curve for HST and NT-proBNP and established the optimal cutoff using the distance from (0,1). We performed subgroup analyses limited to patients with intermediate-risk PE. RESULTS: We screened 815 PE patients from 10/2012 – 06/2021 with an NT-proBNP value measured, of whom 727 were hemodynamically stable. The high-sensitivity troponin assay was first implemented at MGH in April 2018; therefore, we screened 368 consecutive PE patients from 04/2018 – 06/2021, of whom 243 were hemodynamically stable. Of those, 234 (96%) had HST values measured. For both the HST and NT-proBNP populations, the mean age was 62 ± 17 years and 53% were male (Tables 8-9). Overall, the AUC for HST was 0.64 (95% CI, 0.56-0.71) with an optimal cutoff of 46 ng/L (Figure 6a), corresponding to sensitivity 59% (95% CI, 49%-69%) and specificity 61% (95% CI, 53%-69%). The AUC for NT-proBNP overall was 0.56 (95% CI, 0.51-0.61) with an optimal cutoff of 1092 pg/mL (Figure 7a), corresponding to sensitivity 53% (95% CI, 45%-61%) and specificity 59% (95% CI, 55%-63%). Among intermediate-risk PE, the AUC for HST was 0.60 (95% CI, 0.52-0.69) with an optimal cutoff of 46 ng/L (Figure 6b), sensitivity 62% (95% CI, 50%-73%) and specificity 53% (95% CI, 44%-63%); and the AUC for NT-proBNP was 0.56 (95% CI, 0.48-0.64) with an optimal cutoff of 1158 pg/mL (Figure 7b), sensitivity 57% (95% CI, 46%-68%) and specificity 56% (95% CI, 47-64%). CONCLUSION: We identified an optimal cutoff for HST of 46 ng/L and for NT-proBNP of 1092 pg/mL, though the AUC suggests low to moderate performance for the risk stratification of hemodynamically stable PE."]},{"key":"dc:title","label":"Title","values":["The optimal cutoff values of high-sensitivity troponin and NT-proBNP for the risk-stratification of patients with acute pulmonary embolism"]}]}],"canonical_facts":{"dc:contributor.advisor":["Trinkaus-Randall, Vickery E.","Kabrhel, Christopher"],"dc:creator":["Matthews, Timothy M."],"dc:date.accessioned":["2024-03-05T19:07:25Z"],"dc:date.available":["2024-03-05T19:07:25Z"],"dc:date.issued":["2023"],"dc:date.updated":["2024-03-01T20:04:40Z"],"dc:description.abstract":["BACKGROUND: Current guidelines recommend using high-sensitivity troponin T (HST) to risk-stratify hemodynamically stable patients with acute pulmonary embolism (PE). N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can also be used in the risk-stratification of acute PE patients, but there are no established cutoff values for either of these assays to identify PE patients at risk for clinical decompensation. AIMS: To determine the optimal cutoff of HST and NT-proBNP for the risk-stratification of acute PE. METHODS: We retrospectively analyzed data from a prospectively collected, single-center registry of patients evaluated by our Pulmonary Embolism Response Team (PERT). This registry is IRB approved with a waiver of informed consent. We included patients with a confirmed PE who had either an HST value (Elecsys Troponin T Gen 5 STAT, Roche Diagnostics) or NT-proBNP value (Elecsys proBNP II STAT, Roche Diagnostics) measured clinically. We used the highest HST and NT-proBNP value within 24 hours of PERT activation. We excluded patients with unstable vital signs on presentation. Our primary outcome was a composite of death, thrombolysis, thrombectomy, endotracheal intubation, extracorporeal membrane oxygenation (ECMO), or ICU admission, within 7 days. We calculated the area under the ROC curve for HST and NT-proBNP and established the optimal cutoff using the distance from (0,1). We performed subgroup analyses limited to patients with intermediate-risk PE. RESULTS: We screened 815 PE patients from 10/2012 – 06/2021 with an NT-proBNP value measured, of whom 727 were hemodynamically stable. The high-sensitivity troponin assay was first implemented at MGH in April 2018; therefore, we screened 368 consecutive PE patients from 04/2018 – 06/2021, of whom 243 were hemodynamically stable. Of those, 234 (96%) had HST values measured. For both the HST and NT-proBNP populations, the mean age was 62 ± 17 years and 53% were male (Tables 8-9). Overall, the AUC for HST was 0.64 (95% CI, 0.56-0.71) with an optimal cutoff of 46 ng/L (Figure 6a), corresponding to sensitivity 59% (95% CI, 49%-69%) and specificity 61% (95% CI, 53%-69%). The AUC for NT-proBNP overall was 0.56 (95% CI, 0.51-0.61) with an optimal cutoff of 1092 pg/mL (Figure 7a), corresponding to sensitivity 53% (95% CI, 45%-61%) and specificity 59% (95% CI, 55%-63%). Among intermediate-risk PE, the AUC for HST was 0.60 (95% CI, 0.52-0.69) with an optimal cutoff of 46 ng/L (Figure 6b), sensitivity 62% (95% CI, 50%-73%) and specificity 53% (95% CI, 44%-63%); and the AUC for NT-proBNP was 0.56 (95% CI, 0.48-0.64) with an optimal cutoff of 1158 pg/mL (Figure 7b), sensitivity 57% (95% CI, 46%-68%) and specificity 56% (95% CI, 47-64%). CONCLUSION: We identified an optimal cutoff for HST of 46 ng/L and for NT-proBNP of 1092 pg/mL, though the AUC suggests low to moderate performance for the risk stratification of hemodynamically stable PE."],"dc:identifier.uri":["https://hdl.handle.net/2144/48310"],"dc:language.iso":["en_US"],"dc:subject":["Medicine"],"dc:title":["The optimal cutoff values of high-sensitivity troponin and NT-proBNP for the risk-stratification of patients with acute pulmonary embolism"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:21:04Z"}